Compass Therapeutics Inc. (CMPX)
Compass Therapeutics Inc. (CMPX) Stock Price, Analysis & Data
No data available
| Bid | 1.75 |
| Market Cap | 430.41M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -73.45M |
| Beta | 0.82 |
| EPS (ttm) | -0.39 |
| PE Ratio (ttm) | n/a |
| Forward PE | -4.57 |
| P/B (ttm) | 2.59 |
| P/S (ttm) | n/a |
| Earnings Date | Nov 5, 2026 |
| Ask | 2.9 |
| Volume | 2,914,671 |
| Avg. Volume (20D) | 3,515,603 |
| Open | 2.28 |
| Previous Close | 2.31 |
| Day's Range | 2.24 - 2.44 |
| 52-Week Range | 1.61 - 6.88 |
| Analyst | Strong Buy |
| Price Target | 7 (192.89%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About CMPX
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, develops antibody-based therapeutics for the treatment of various human diseases in the United States. The company's lead product candidate, tovecimig, is a bispecific antibody that targets delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF-A), which are critical to angiogenesis and tumor vascularization. It also develops CTX-471, an Ig...
Financial Performance
In 2025, Compass Therapeutics's revenue was 0, a decrease of -100% compared to the previous year's 850K. Earnings were -66.49M, an increase of 34.66%.
Financial StatementsAnalyst Forecast
According to 12 analyst ratings, the average rating for CMPX stock is "Strong Buy". The 12-month stock price forecast is 7, which is upside of 192.89% from the latest price.
Stock ForecastsEarnings Surprise
Analysts project revenue of ... Upgrade
